Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BACE inhibitor
Biotech
Biogen, Eisai throw out remaining Alzheimer's BACE hope
One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.
Ben Adams
Sep 13, 2019 8:55am
Weak data spur Amgen, Novartis to can pivotal Alzheimer's test
Jul 12, 2019 8:30am
Lilly's latest BACE setback echoes Alzheimer's R&D hurdles
Nov 7, 2018 11:31am
Biogen, Eisai turn around previously bleak Alzheimer’s study
Jul 6, 2018 9:50am
Lilly, AstraZeneca can phase 3 Alzheimer’s trials
Jun 12, 2018 5:12am
Eisai, Biogen get mixed results for their BACE drug in early AD
Jun 6, 2018 8:12am
